Stockscreener 앱 받기
105.16
0.50%
0.52
시간 외 거래:
105.16
전일 마감가:
$104.64
열려 있는:
$104.53
하루 거래량:
487.68K
Relative Volume:
0.73
시가총액:
$5.18B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-16.10
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+0.09%
1개월 성능:
-4.33%
6개월 성능:
+7.07%
1년 성능:
+41.71%
1일 변동 폭
$102.55
$105.55
1주일 범위
$101.41
$106.77
52주 변동 폭
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
105.16 | 5.17B | 338.46M | -310.96M | -132.82M | -6.53 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Mark Coleman Sells 3,750 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
How To Trade (AXSM) - news.stocktradersdaily.com
TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wellington Management Group LLP Has $56.96 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Insider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 20,000 Shares of Stock - MarketBeat
Insider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 20,673 Shares of Stock - MarketBeat
Zacks Research Issues Optimistic Estimate for AXSM Earnings - MarketBeat
Hedge Fund and Insider Trading News: Chris Rokos, Ray Dalio, Paul Marshall, Edward Charles Molson, Third Point, Soroban Capital Partners, Whale Rock Capital Management, Elliott Management, Vestis Corp (VSTS), Axsome Therapeutics Inc (AXSM), and - Insider Monkey
Axsome Therapeutics Sets Strong Institutional Presence with Three Elite Healthcare Conference Presentations - Stock Titan
Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Nuveen Asset Management LLC Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ProShare Advisors LLC Acquires 2,942 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares By Investing.com - Investing.com India
Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares - Investing.com Australia
Axsome Therapeutics Secures US$570 Million Financing and Equity Investment from Blackstone - Global Legal Chronicle
Axsome settles patent dispute with Hetero Labs over Sunosi generic - MSN
Axsome Unveils Breakthrough Data from 3 CNS Programs: New Results for Depression, Alzheimer's, and Sleep Disorders - Stock Titan
Axsome, Hetero Settle Patent Fight on Daytime-Sleepiness Drug - Bloomberg Law News
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News
Axsome's solriamfetol shows mixed results amid 13 phase III wins in April - BioWorld MedTech
Axsome Therapeutics (AXSM) Resolves Patent Dispute Over Sunosi G - GuruFocus
Axsome Reaches Settlement With Hetero Labs Over Sunosi Patent Dispute; Shares Up Pre-Bell - marketscreener.com
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero Labs - marketscreener.com
Axsome settles patent lawsuit with Hetero over SUNOSI By Investing.com - Investing.com Nigeria
Axsome settles Sunosi patent dispute with Hetero (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics (AXSM) Settles Patent Dispute Over SUNOSI | - GuruFocus
Axsome Therapeutics Settles Patent Litigation on SUNOSI - TipRanks
Axsome Agrees With Hetero Labs To Settle Patent Litigation Related To SUNOSI - Nasdaq
Axsome settles patent lawsuit with Hetero over SUNOSI - Investing.com
Axsome Therapeutics Enters Settlement with Hetero Labs to Resolve SUNOSI® Patent Litigation - Nasdaq
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. - The Manila Times
Axsome Wins 17 Years of Market Exclusivity for SUNOSI in Patent Settlement with Hetero - Stock Titan
Cetera Investment Advisers Has $601,000 Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Axsome Therapeutics' (AXSM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Woodline Partners LP - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Invests $2.85 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.14 Average Target Price from Analysts - MarketBeat
Axsome Therapeutics’ SWOT analysis: stock poised for growth amid CNS market expansion - Investing.com India
3 High-Flying Stocks That Could Soar Even More - AOL.com
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Axsome Therapeutics (AXSM) and Biogen (BIIB) - The Globe and Mail
Captrust Financial Advisors Decreases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - Defense World
Man Group plc Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
TFG Asset Management GP Ltd Buys Shares of 41,250 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Deutsche Bank AG - MarketBeat
AXSM: HC Wainwright & Co. Reiterates Buy Rating with $180 Price - GuruFocus
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts - Benzinga
AXSM: HC Wainwright & Co. Reiterates Buy Rating with $180 Price Target | AXSM Stock News - GuruFocus
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by RTW Investments LP - MarketBeat
(AXSM) Long Term Investment Analysis - news.stocktradersdaily.com
Axsome Therapeutics director Mark Coleman sells $322,473 in stock - Investing.com Australia
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):